Clinical Trial Grants support Phase II/III clinical trials of novel, high-potential treatments for MND/ALS within the Australian Clinical Trials Consortium.
These grants are awarded with an offer of up to AUD $1,800,000 (Phase II/III trial), with project performance of up to 3 years.
Eligibility: Applications are open to MND/ALS researchers globally. Australian trial sites and participants are mandatory.
Click below to download a copy of:
- The Clinical Trial Grants Criteria
- The manual on how to submit a Letter of Intent and a Full Application (if invited) for a Clinical Trial Grant using Fluxx
Videos to guide your submission using the FightMND Grant Management System – Fluxx: